0001209191-20-013408.txt : 20200227
0001209191-20-013408.hdr.sgml : 20200227
20200227161628
ACCESSION NUMBER: 0001209191-20-013408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200225
FILED AS OF DATE: 20200227
DATE AS OF CHANGE: 20200227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kowalski Mark
CENTRAL INDEX KEY: 0001628357
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 20662238
MAIL ADDRESS:
STREET 1: C/O ARBUTUS BIOPHARMA CORP.
STREET 2: 100-8900 GLENLYON PARKWAY
CITY: BURNABY
STATE: A1
ZIP: V5J 5J8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ? 885 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 3E8
BUSINESS PHONE: 604-558-6536
MAIL ADDRESS:
STREET 1: 2150 ? 885 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 3E8
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-25
0
0001290149
Sierra Oncology, Inc.
SRRA
0001628357
Kowalski Mark
C/O SIERRA ONCOLOGY, INC.
2150 885 WEST GEORGIA ST.
VANCOUVER
A1
V6C 3E8
BRITISH COLUMBIA, CANADA
0
1
0
0
Chief Medical Officer
Stock Option (right to buy)
13.31
2020-02-25
4
A
0
75030
0.00
A
2030-02-25
Common Stock
75030
75030
D
The option vests as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Sukhi Jagpal as attorney-in-fact for Mark Kowalski, M.D., Ph.D.
2020-02-27